Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.38 |
| ▸ | ACE | P12821 | 3/20 | 0.38 |
| ▸ | FNTA | P49354 | 4/20 | 0.37 |
| ▸ | FNTB | P49356 | 4/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.36 |
| ▸ | MME | P08473 | 1/20 | 0.36 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.35 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 2/20 | 0.33 |
| ▸ | CTSS | P25774 | 2/20 | 0.33 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | CTSV | O60911 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4600447 | 1.00 | ACE2 (0.38) | ACE2ACEFNTAFNTBMCL1 | |
| SCHEMBL14602509 | 0.85 | ACACB (0.43) | FNTAFNTBMCL1PGGT1B | |
| SCHEMBL5598931 | 0.83 | SLC15A2 (0.41) | ACE2ACEFNTAFNTBCAPN1 | |
| SCHEMBL8824843 | 0.81 | KDM4E (0.41) | ACE2ACEFNTAFNTBCAPN1 | |
| SCHEMBL8824831 | 0.81 | KDM4E (0.41) | ACE2ACEFNTAFNTBCAPN1 | |
| Anserine SCHEMBL2771107 | 0.81 | FNTA (0.39) | ACE2ACEFNTAFNTBCAPN1 | |
| Anserine SCHEMBL34255 | 0.81 | FNTA (0.39) | ACE2ACEFNTAFNTBCAPN1 | |
| Anserine SCHEMBL2685222 | 0.80 | FNTA (0.39) | ACE2ACEFNTAFNTBCAPN1 | |
| Anserine SCHEMBL6060539 | 0.80 | FNTA (0.39) | ACE2ACEFNTAFNTBCAPN1 | |
| SCHEMBL634586 | 0.79 | ITGA4 (0.45) | ACE2ACEFNTAFNTBMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7164028-B2 | Method for preparing β-alaninamides | LONZA AG (CH) | 2007-01-16 | — | — | US | disclosed |
| US-20050192354-A1 | Method for preparing beta-alaninamides | HILDBRAND STEFAN (CH) | 2005-09-01 | — | — | US | disclosed |
| US-6878829-B2 | Method for producing β-alaninamides | LONZA AG (CH) | 2005-04-12 | — | — | US | disclosed |
| US-20030105335-A1 | Method for producing beta-alaninamides | LONZA AG (CH) | 2003-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105335-A1 | Method for producing beta-alaninamides | AHCY, AAAS, ARGLU1 | ACE2 392/4885ACE 450/4885FNTA 1508/4885 |
| US-20050192354-A1 | Method for preparing beta-alaninamides | AAAS, ASPH, BCAT2 | ACE2 512/4885ACE 262/4885FNTA 475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.